Docoh
Loading...

250 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-Q
2000 Q2
PRPO Precipio Inc
28 Aug 00
Quarterly report
8:00pm
Sales Cost of Goods sold Gross Profit Operating Expenses: Selling, General and Administrative Research and Development Stock Based Compensation … of $18.6 million. Our losses have resulted principally from costs incurred in research and development and selling, general and administrative costs
10-K
2000 FY
PRPO Precipio Inc
15 Mar 01
Annual report
7:00pm
applications for the WAVE and expect further improvements to be available in the future. Research and Development During fiscal years 2000, 1999 and 1998 … , we spent $7.7 million, $6.3 million and $3.2 million, respectively, on research and development activities. We continue to maintain an active
10-Q
2001 Q3
PRPO Precipio Inc
7 Nov 01
Quarterly report
7:00pm
sold Gross profit Operating expenses: Selling, general and administrative Research and development Stock based compensation expense Total operating … significant losses resulting principally from costs incurred in research and development and selling, general and administrative costs associated with our
10-Q
2001 Q2
PRPO Precipio Inc
13 Aug 01
Quarterly report
8:00pm
Operating expenses: Selling, general and administrative Research and development Stock based compensation expense Loss from operations Interest income … as a percentage of our net sales. We have incurred significant losses resulting principally from costs incurred in research and development and selling
10-Q
2003 Q2
PRPO Precipio Inc
11 Aug 03
Quarterly report
8:00pm
Research and development Restructuring and restructuring related charges (Note J) Stock based compensation expense Loss from operations Other income … million. We expect to continue to incur substantial research and development and selling, general and administrative costs. Critical Accounting Policies
10-Q
fke7d kqgp5vbclgn7r
13 Nov 03
Quarterly report
7:00pm
10-Q
qxzva bxsj6url
12 Nov 00
Quarterly report
7:00pm
10-K
g7o5d0m7
24 Mar 02
Annual report
7:00pm
10-K
74790af50 b2tmwdc
30 Mar 03
Annual report
7:00pm
10-Q
e1v5a
13 May 01
Quarterly report
8:00pm
10-Q
7c7099w838rcq6wu3cv
13 Aug 02
Quarterly report
8:00pm
10-Q
b1d61q71wm4 gqn
12 May 03
Quarterly report
8:00pm
424B3
3ojbwqlpp7u1ee4
17 Sep 00
Prospectus supplement
8:00pm
10-K/A
eu3htudnsbrvo1hpxvbt
26 May 05
Annual report (amended)
8:00pm
10-K
pfneelvx1bjkxj
14 Apr 05
Annual report
8:00pm
10-K
gs5geifdvf uw6pxo
27 Mar 08
Annual report
8:00pm
8-K/A
EX-99.2
gstsn743a v67t
13 Mar 11
Financial Statements and Exhibits
8:00pm
8-K
EX-99.1
y9bvxpoyuk 71u3pr
29 May 03
Transgenomic Announces Changes In Management Responsibilities In Line with Evolving Business Segment Focus
8:00pm
10-K
zpr szs70z
1 Apr 07
Annual report
8:00pm
S-1/A
ypytov7l41lxr7 dm6
9 Jan 01
IPO registration (amended)
7:00pm